拉罗替尼商品名是什么？用于治疗哪些癌症的靶向药及价格医保详解

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKB, TRKC, and TRK2), shutting down the signaling pathways that lead to the growth of TRK fusion-related tumors. Larotrectinib is a "cancer-agnostic" therapy; it is the world's first oral TRK inhibitor specifically designed for patients with NTRK gene fusion-related cancers. NTRK gene fusions are found in various solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and lung cancer, especially in some rare cancers such as infantile fibrosarcoma, secretory carcinoma-like breast cancer, and secretory breast cancer...

Larotrectinib is a potent, oral, selective tropomyosin receptor kinase (TRK) inhibitor designed to directly target TRKs (including TRKB, TRKC, and TRK2), shutting down the signaling pathways that lead to the growth of TRK fusion-related tumors. Larotrectinib is a "cancer-agnostic" therapy; it is the world's first oral TRK inhibitor specifically designed for patients with NTRK gene fusion-related cancers. NTRK gene fusions are found in various solid tumor types, including pancreatic cancer, thyroid cancer, salivary gland cancer, breast cancer, colorectal cancer, and lung cancer, especially in some rare cancers such as infantile fibrosarcoma, secretory carcinoma-like breast cancer, and secretory breast cancer...

Dabrafenib is a BRAF inhibitor cancer drug, available as a mesylate. On May 29, 2013, the U.S. Food and Drug Administration (FDA) simultaneously approved the marketing applications of dabrafenib and trametinib. Dabrafenib is approved for the treatment of unresectable melanoma (tumors that cannot be surgically removed) and metastatic melanoma (tumors that have spread to other organs) harboring the BRAF V6 Chemicalbook00E mutation, but not for the treatment of wild-type BRAF melanoma. Mekinist is used to treat BRAF V600E or V600...

In 2018, the FDA approved the prescription drug larotrectinib for marketing in the United States for targeting the fusion proteins of neurotrophic tyrosine receptor kinases (NTRK1, NTRK2, NTRK3). Patients must use it strictly as directed by their doctor.

Afatinib works by irreversibly blocking ErbB family receptors (including EGFR, HER2, etc.), shutting down cancer cell signaling pathways and inhibiting tumor growth.

Regorafenib is a multi-target tyrosine kinase inhibitor primarily used to treat metastatic colorectal cancer (mCRC).